List of Excipients in Branded Drug QBRELIS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals Inc	QBRELIS	lisinopril	52652-3001	CITRIC ACID MONOHYDRATE
Azurity Pharmaceuticals Inc	QBRELIS	lisinopril	52652-3001	HYDROCHLORIC ACID
Azurity Pharmaceuticals Inc	QBRELIS	lisinopril	52652-3001	SODIUM BENZOATE
Azurity Pharmaceuticals Inc	QBRELIS	lisinopril	52652-3001	SODIUM CITRATE
Azurity Pharmaceuticals Inc	QBRELIS	lisinopril	52652-3001	SODIUM HYDROXIDE

Qbrelis Excipient Strategy and Commercial Opportunities for Lisinopril Oral Solution

Last updated: August 27, 2026

Qbrelis is a ready-to-use 1 mg/mL lisinopril oral solution developed for patients who have difficulty swallowing tablets, including pediatric patients and adults requiring dose flexibility. Its commercial differentiation depends less on the active ingredient, which is generic lisinopril, and more on excipient selection, palatability, dosing accuracy, stability, packaging, and access to pediatric and institutional markets. The largest opportunity is to extend the oral-solution platform into age-appropriate cardiovascular products while protecting formulation, device, and manufacturing know-how.

What is Qbrelis and who manufactures it?

Qbrelis contains lisinopril, an angiotensin-converting enzyme inhibitor. The product is supplied as an oral solution with a concentration of 1 mg/mL. The U.S. Food and Drug Administration approved Qbrelis under NDA 207635 in December 2016. The product is marketed by Azurity Pharmaceuticals, which acquired Silvergate Pharmaceuticals, the original developer of several specialty liquid medicines.[1][2]

Qbrelis is indicated for:

• Hypertension in adults and pediatric patients aged 6 years and older.
• Adjunctive treatment of heart failure in adults.
• Reduction of mortality in hemodynamically stable patients after acute myocardial infarction.[1]

The oral-solution format permits direct administration without tablet crushing, suspension preparation, or pharmacy compounding. At 1 mg/mL, a 5 mg dose equals 5 mL, while a 20 mg dose equals 20 mL. The concentration is commercially intuitive, but higher doses create a liquid-volume burden that can affect adherence.

Qbrelis product profile

Attribute	Qbrelis
Active ingredient	Lisinopril
Dosage form	Oral solution
Strength	1 mg/mL
U.S. application	NDA 207635
FDA approval	December 2016
Primary therapeutic class	ACE inhibitor
Pediatric labeling	Hypertension in patients aged 6 years and older
Administration	Oral syringe or other calibrated measuring device
Prescription status	Prescription drug
Primary differentiation	Ready-to-use liquid formulation
Reference tablet ingredient	Lisinopril dihydrate or lisinopril, depending on product labeling

Qbrelis does not compete primarily against other branded ACE inhibitors. Its principal alternatives are lisinopril tablets, extemporaneously compounded liquids, crushed tablets mixed with food or liquids, and other commercial liquid ACE inhibitors.

What excipients are used in Qbrelis?

The Qbrelis prescribing information identifies inactive ingredients that support pH control, taste acceptance, preservation and physical stability. Public labeling identifies citric acid, sodium citrate, sucralose, natural flavor and purified water among the inactive ingredients.[1]

The formulation strategy is consistent with the requirements of a chronic oral liquid:

1. Maintain lisinopril stability in an aqueous environment.
2. Provide sufficient buffering without creating excessive sodium exposure.
3. Improve palatability for pediatric and geriatric patients.
4. Avoid sucrose and reduce dental and metabolic concerns.
5. Deliver a uniform dose throughout the labeled shelf life.
6. Support administration with an oral syringe.

Functional role of Qbrelis excipients

Excipient or excipient class	Likely commercial function	Strategic relevance
Citric acid	Acidification and pH adjustment	Supports chemical stability and taste balance
Sodium citrate	Buffering agent	Controls pH and reduces batch-to-batch variability
Sucralose	High-intensity sweetener	Improves taste without sucrose or high sugar load
Natural flavor	Taste masking	Addresses lisinopril bitterness and acidic sensory profile
Purified water	Vehicle	Supports ready-to-use oral-liquid delivery

The formulation’s use of sucralose rather than sucrose is commercially relevant. Sucrose-containing liquids may create concerns for dental health, diabetes management and caloric intake. A non-sugar sweetener allows the product to be positioned for chronic use in pediatric and adult populations.

The key technical issue is not simply whether lisinopril dissolves. It is whether the finished product maintains assay, impurity control, appearance, taste and dose uniformity over time. Lisinopril is highly water soluble, but aqueous formulations still require control of pH, oxidation, microbial quality and packaging compatibility.

How does the Qbrelis excipient strategy create commercial value?

The excipient strategy creates value through product usability rather than pharmacological differentiation. Lisinopril tablets are widely available at low prices. Qbrelis can command a premium only when it solves a specific administration problem.

Pediatric dosing and adherence

Qbrelis supports weight-based or individually titrated dosing without tablet splitting. This matters in pediatric hypertension, where prescribed doses may not align with available tablet strengths.

The 1 mg/mL concentration also simplifies calculations:

• 0.1 mL equals 0.1 mg.
• 1 mL equals 1 mg.
• 5 mL equals 5 mg.
• 10 mL equals 10 mg.

The direct mg-to-mL relationship reduces conversion errors. The commercial limitation is that some adult doses require large volumes. A higher-strength version, such as 2 mg/mL, could reduce administration volume, but it would create regulatory and medication-error risks if both strengths were marketed simultaneously.

Avoidance of pharmacy compounding

Compounded lisinopril liquids can vary in concentration, flavor, beyond-use dating, packaging and availability. A commercially manufactured product provides standardized composition, labeling and quality controls. This is particularly valuable for hospitals, pediatric clinics, specialty pharmacies and caregivers managing long-term treatment at home.

The product also reduces the need for caregivers to crush tablets and mix them with food. That practice can create dose-loss and palatability problems, especially when the full mixture is not consumed.

Taste masking

Lisinopril is not generally selected for its taste. Qbrelis uses a sweetener-flavor system to improve acceptability. Taste masking is a material commercial barrier because a generic applicant must demonstrate more than chemical equivalence. It must also produce a liquid that patients and caregivers will accept.

Potential formulation workstreams include:

• Flavor screening across fruit, citrus and neutral profiles.
• Sweetener optimization to reduce aftertaste.
• Control of acidity to balance stability and sensory performance.
• Evaluation of taste after storage rather than only at release.
• Compatibility testing with oral syringes and dosing cups.
• Assessment of flavor carryover and container adsorption.

A generic product with the same concentration but inferior taste could be clinically substitutable yet commercially weak in pediatrics.

What formulation patents protect Qbrelis?

Public FDA labeling and the Drugs@FDA record establish the approved product and its composition, but they do not by themselves provide a complete patent landscape. The Orange Book must be reviewed for current patent listings associated with NDA 207635, including any changes after approval.[3]

For a product such as Qbrelis, the most commercially relevant intellectual-property categories are:

• Lisinopril oral-solution compositions.
• Specific pH and buffer ranges.
• Sweetener and flavor combinations.
• Preservative systems, if applicable.
• Stability-enhancing excipient combinations.
• Container-closure systems.
• Oral dosing devices.
• Manufacturing processes that improve assay uniformity or impurity control.
• Pediatric methods of use or administration.

A formulation patent is strongest when it claims a narrow combination that produces a measurable technical effect, such as improved stability, reduced degradation, increased palatability or improved dose uniformity. Broad claims covering lisinopril dissolved in water are more vulnerable to invalidity or design-around arguments because the active ingredient and liquid dosage form are conventional.

How strong is the Qbrelis patent estate?

The commercial strength of the Qbrelis estate should be assessed across four separate layers:

Layer	Potential strength	Main challenge
Active ingredient	Low, because lisinopril is long generic	No meaningful molecule exclusivity
Oral-solution formulation	Moderate if narrow excipient and pH claims exist	Design-around through alternative buffers or flavors
Device and packaging	Moderate	Competing calibrated syringes and containers
Manufacturing know-how	Potentially high as a trade secret	Reverse engineering and alternative process development

The absence of meaningful active-ingredient exclusivity makes formulation and execution central. Even a valid formulation patent may not prevent all generic entry if an applicant can develop a different excipient system that meets FDA requirements.

When does Qbrelis lose exclusivity?

Qbrelis has no new-molecular-entity exclusivity because lisinopril was approved decades before Qbrelis. The product’s market protection therefore depends on any applicable formulation, method-of-use or regulatory exclusivity associated with NDA 207635.

The U.S. exclusivity analysis should separate three concepts:

1. NCE exclusivity: Not applicable to Qbrelis.
2. Pediatric exclusivity: A six-month extension may apply only if FDA granted it based on a qualifying written request and completed pediatric studies.
3. Patent protection: Depends on patents listed in the Orange Book and their expiration dates.

FDA approval alone does not establish a long period of market exclusivity for a reformulated generic active ingredient. The Orange Book patent listing and FDA exclusivity records are the controlling sources for current entry analysis.[3][4]

What Paragraph IV challenges and generic entry risks exist?

A generic applicant seeking approval for a lisinopril oral solution could file an ANDA with a Paragraph IV certification against listed patents. The applicant would argue that the listed patent is invalid, unenforceable or not infringed. A Paragraph IV notice can trigger patent litigation under the Hatch-Waxman Act, with a potential 30-month stay of approval under applicable conditions.[5]

The main generic entry routes are:

Route 1: Same-strength oral solution

A competitor could develop a 1 mg/mL lisinopril solution with a different flavor, sweetener, buffer or preservative system. This is the most direct commercial threat.

Route 2: Alternative concentration

A 2 mg/mL or other concentration could reduce volume for adults. It may avoid claims limited to 1 mg/mL but could face a separate medication-use challenge because concentration changes increase dosing errors.

Route 3: Compounded-product substitution

503A pharmacies and 503B outsourcing facilities may supply compounded lisinopril liquids in certain circumstances. Commercial demand is strongest where Qbrelis is unavailable, expensive or excluded from formularies. Compounding does not necessarily create an ANDA-style generic competitor, but it can reduce branded demand.

Route 4: Competing ACE-inhibitor liquids

Enalapril and captopril liquid products can compete for patients who need non-tablet ACE-inhibitor therapy. Clinical interchangeability is limited because the products have different dosing, indications and stability profiles, but hospitals may evaluate them together for formulary purposes.

What FDA regulatory issues affect Qbrelis formulation strategy?

Any new Qbrelis formulation would require a regulatory pathway appropriate to the proposed change. A new strength, new excipient system or new dosage device could require a supplemental NDA, while a competitor would generally pursue an ANDA or other abbreviated pathway depending on the reference product and formulation differences.[4]

Key regulatory issues include:

• Demonstration of pharmaceutical equivalence.
• Finished-product assay and impurity control.
• Stability under long-term and accelerated conditions.
• Microbial limits and preservative effectiveness where relevant.
• Container-closure integrity.
• Dose delivery accuracy through the labeled device.
• Labeling that prevents confusion between concentrations.
• Pediatric acceptability and administration instructions.
• Compatibility with feeding tubes if such use is pursued.
• Extractables and leachables from bottles, caps and syringes.

Excipient changes can affect bioavailability, palatability, pH, chemical stability and dosing-device performance. They should be treated as product-defining variables, not as low-risk substitutions.

What commercial opportunities exist for Qbrelis?

Higher-concentration lisinopril oral solution

A concentrated product could improve adult usability and reduce shipping and storage volume. The main commercial requirement would be clear differentiation in packaging, color, labeling and device markings. A 2 mg/mL version could be positioned for adults and larger children, while 1 mg/mL remains the pediatric titration product.

Institutional and pediatric specialty distribution

Priority channels include:

• Children’s hospitals.
• Pediatric cardiology and nephrology clinics.
• Specialty pharmacies.
• Long-term-care facilities.
• Home health providers.
• Hospital discharge programs.

A bundled product with a calibrated oral syringe, caregiver instructions and electronic dosing support could improve adherence and reduce medication errors.

Unit-dose and adherence packaging

Single-use or short-course unit-dose packaging could target hospitals and transitional care. For chronic outpatient use, a bottle-and-syringe package remains more economical. Packaging should focus on accurate withdrawal, child resistance, light protection and minimized product waste.

Platform expansion

The most valuable opportunity may be a broader liquid cardiovascular platform. Candidate products include other antihypertensives, heart-failure medicines and renal-care therapies where tablet swallowing, dose titration or pediatric administration is difficult.

A platform strategy can reuse:

• Flavor development.
• Bottle and syringe systems.
• Stability protocols.
• Pediatric usability studies.
• Specialty-pharmacy relationships.
• Regulatory expertise for liquid dosage forms.

Licensing opportunities

Potential counterparties include generic manufacturers with low-cost active pharmaceutical ingredient supply, specialty-pharmaceutical companies with pediatric commercial infrastructure, and device companies with oral dosing systems.

Licensing value would depend on the scope of formulation patents, regulatory exclusivity, manufacturing cost, reimbursement coverage and documented demand from pediatric institutions. A license based only on the lisinopril active ingredient would have limited value because multiple suppliers manufacture lisinopril. The more defensible assets are the finished formulation, branded commercial rights, clinical-use data, device configuration and manufacturing process.

How does Qbrelis compare with lisinopril tablets and compounded liquids?

Factor	Qbrelis	Lisinopril tablets	Compounded lisinopril liquid
Administration	Ready-to-use liquid	Requires swallowing or manipulation	Ready-to-use but pharmacy dependent
Dose flexibility	High	Moderate to low	High
Taste control	Standardized	Not relevant unless crushed	Variable
Availability	Product and distributor dependent	Broad	Local or specialty pharmacy dependent
Manufacturing consistency	Commercial GMP product	Commercial GMP product	Depends on compounder
Cost position	Usually higher	Usually lowest	Variable
Pediatric usability	Strong	Limited in some patients	Potentially strong
Patent exposure	Formulation and device	Generally mature generic market	Usually outside ANDA patent pathway
Volume burden	Can be high at adult doses	Low	Depends on concentration

What is the revenue exposure and competitive outlook?

Publicly available sources do not provide a separately reported Qbrelis revenue figure. The product’s revenue exposure is therefore best evaluated through market structure rather than reported product sales.

The main revenue risks are:

• Low-cost lisinopril tablets.
• Generic oral-solution entry.
• Hospital substitution with compounded products.
• Payer rejection of premium liquid pricing.
• Limited adult demand because many adults can take tablets.
• Volume burden at higher doses.
• Concentration confusion if competing liquid products enter the market.

The strongest demand segments are patients with dysphagia, pediatric hypertension, enteral-administration needs and caregiver-managed dosing. The product has less pricing power in routine adult hypertension, where tablet lisinopril is widely available and inexpensive.

Key Takeaways

• Qbrelis is a 1 mg/mL lisinopril oral solution approved by FDA in 2016 under NDA 207635.
• Its value comes from ready-to-use delivery, dose flexibility, pediatric usability and avoidance of tablet manipulation.
• Citric acid, sodium citrate, sucralose, natural flavor and purified water form the disclosed excipient foundation.
• The strongest potential IP is likely to reside in formulation combinations, stability, packaging, dosing devices and manufacturing know-how rather than lisinopril itself.
• Generic entry could occur through a different buffer, sweetener, flavor or concentration if relevant formulation claims can be designed around.
• A higher-concentration product, institutional packaging and a broader pediatric cardiovascular liquid platform are the most credible commercial expansion paths.
• Qbrelis faces structural pricing pressure from lisinopril tablets and compounded liquids.
• Orange Book listings, FDA exclusivity records and current litigation dockets should control any definitive launch-risk assessment.

FAQs

Is Qbrelis sugar-free?

Qbrelis labeling identifies sucralose as a sweetener and does not identify sucrose as an inactive ingredient.[1]

Can Qbrelis be used in children under six years old?

The FDA-approved hypertension indication covers pediatric patients aged 6 years and older. Use outside the labeled age range requires separate clinical and regulatory assessment.[1]

Does Qbrelis contain alcohol?

The approved labeling should be used to determine the complete inactive-ingredient profile. Alcohol should not be assumed to be present merely because Qbrelis is an oral liquid.[1]

Is Qbrelis interchangeable with lisinopril tablets?

Qbrelis contains the same active ingredient, but substitution should follow applicable prescribing, pharmacy and regulatory requirements. The dosage form and concentration create administration and dosing considerations.

Could a 2 mg/mL Qbrelis product be commercially attractive?

Yes. A higher concentration could reduce adult dosing volume and shipping costs. Its feasibility would depend on stability, palatability, dose-device accuracy, labeling controls, regulatory requirements and the risk of concentration-related medication errors.

References

1. U.S. Food and Drug Administration. (2023). Qbrelis (lisinopril) oral solution: Prescribing information. FDA.

2. Azurity Pharmaceuticals, Inc. (n.d.). Qbrelis: Lisinopril oral solution. Azurity Pharmaceuticals.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.

4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. FDA.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.